撤回：二甲双胍与程序性死亡受体配体1（PD-L1）单克隆抗体协同增强肿瘤免疫反应治疗非小细胞肺癌及其分子机制研究
Retracted: Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation.
作者信息
And Alternative Medicine Evidence-Based Complementary
出版信息
Evid Based Complement Alternat Med. 2023 Aug 2;2023:9871939. doi: 10.1155/2023/9871939. eCollection 2023.
Abstract
[This retracts the article DOI: 10.1155/2022/5983959.].
摘要
[本文撤回文章DOI: 10.1155/2022/5983959。]
相似文献
1
Retracted: Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation.撤回：二甲双胍与程序性死亡受体配体1（PD-L1）单克隆抗体协同增强肿瘤免疫反应治疗非小细胞肺癌及其分子机制研究
Evid Based Complement Alternat Med. 2023 Aug 2;2023:9871939. doi: 10.1155/2023/9871939. eCollection 2023.
2
Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation.二甲双胍与程序性死亡受体配体1（PD-L1）单克隆抗体协同增强肿瘤免疫反应在非小细胞肺癌治疗中的应用及其分子机制研究
Evid Based Complement Alternat Med. 2022 Sep 25;2022:5983959. doi: 10.1155/2022/5983959. eCollection 2022.
3
Retracted: Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.撤回：PD-1/PD-L1抑制剂与化疗治疗晚期非小细胞肺癌的临床疗效与安全性分析：一项系统评价与Meta分析。
Biomed Res Int. 2022 Dec 25;2022:9808495. doi: 10.1155/2022/9808495. eCollection 2022.
4
Retracted: The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer.撤稿：微波消融联合抗程序性死亡蛋白1单克隆抗体对非小细胞肺癌患者T细胞亚群及长期预后的影响
Comput Math Methods Med. 2023 Dec 13;2023:9879478. doi: 10.1155/2023/9879478. eCollection 2023.
5
Retracted: Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.撤回：非小细胞肺癌放疗后PD-1/sPD-L1免疫指标表达变化的分子机制
Biomed Res Int. 2024 Jan 9;2024:9865398. doi: 10.1155/2024/9865398. eCollection 2024.
6
Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.肝激酶 B1 上调程序性死亡配体 1 及其在非小细胞肺癌中程序性死亡 1 阻断治疗中的意义。
Life Sci. 2020 Sep 1;256:117923. doi: 10.1016/j.lfs.2020.117923. Epub 2020 Jun 6.
7
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
8
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.抗KIR单克隆抗体与抗PD-1/PD-L1单克隆抗体联合使用可能是克服非小细胞肺癌肿瘤免疫逃逸的关键突破。
Drug Des Devel Ther. 2018 Apr 24;12:981-986. doi: 10.2147/DDDT.S163304. eCollection 2018.
9
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.靶向 PD-L1 降解的 ANXA1 衍生肽抑制多种癌症中的肿瘤免疫逃逸。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006345.
10
Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells.二甲双胍通过激活结直肠癌细胞中的Hippo信号通路来减弱程序性死亡受体配体1（PD-L1）的表达。
Am J Transl Res. 2019 Nov 15;11(11):6965-6976. eCollection 2019.
本文引用的文献
1
Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation.二甲双胍与程序性死亡受体配体1（PD-L1）单克隆抗体协同增强肿瘤免疫反应在非小细胞肺癌治疗中的应用及其分子机制研究
Evid Based Complement Alternat Med. 2022 Sep 25;2022:5983959. doi: 10.1155/2022/5983959. eCollection 2022.
Zotero 插件